William Demant Holding A/S, a hearing healthcare company, develops, manufactures, and sells products and equipment designed to aid the people with hearing loss connect and communication primarily in Denmark, rest of Europe, North America, Oceania, Asia, and other countries. Its products include hearing devices and implants; diagnostic instruments; and personal communication systems, such as headsets and solutions for the professional call center and office market, as well as consumer headsets for the gaming and mobile segments. The company was founded in 1904 and is headquartered in Smørum, Denmark.
Industry, Sector and Symbol
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
Phone45-3917-7300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.00 billion
Profitability
Miscellaneous
Employees13,280
OptionableNot Optionable
WILLIAM DEMANT/ADR (OTCMKTS:WILYY) Frequently Asked Questions
What is WILLIAM DEMANT/ADR's stock symbol?
WILLIAM DEMANT/ADR trades on the OTCMKTS under the ticker symbol "WILYY."
When is WILLIAM DEMANT/ADR's next earnings date?
Has WILLIAM DEMANT/ADR been receiving favorable news coverage?
News stories about WILYY stock have been trending very positive recently, according to InfoTrie. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. WILLIAM DEMANT/ADR earned a daily sentiment score of 3.2 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
Who are some of WILLIAM DEMANT/ADR's key competitors?
Some companies that are related to WILLIAM DEMANT/ADR include Zimmer Biomet (ZBH), COLOPLAST A/S/ADR (CLPBY), Align Technology (ALGN), Smith & Nephew (SNN), Steris (STE), MSA Safety (MSA), Wright Medical Group (WMGI), Inogen (INGN), Avanos Medical (AVNS), Establishment Labs (ESTA), Sientra (SIEN), RTI Surgical (RTIX), Invacare (IVC), Lakeland Industries (LAKE) and ConforMIS (CFMS).
Who are WILLIAM DEMANT/ADR's key executives?
WILLIAM DEMANT/ADR's management team includes the folowing people:
- Mr. Søren Nielsen, Chief Exec. Officer, Pres, Member of Exec. Board and Pres of Oticon A/S (Age 48)
- Mr. René Schneider, Chief Financial Officer and Member of Exec. Board (Age 45)
- Mr. Søren Bergholt Andersson, VP of Investor Relations (Age 41)
- Ms. Trine Kromann-Mikkelsen, VP of Corp. Communication & Relations
- Mr. Jes Olsen, Pres of Oticon Medical
How do I buy shares of WILLIAM DEMANT/ADR?
Shares of WILYY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is WILLIAM DEMANT/ADR's stock price today?
One share of WILYY stock can currently be purchased for approximately $15.19.
How big of a company is WILLIAM DEMANT/ADR?
WILLIAM DEMANT/ADR has a market capitalization of $8.08 billion and generates $2.00 billion in revenue each year. The company earns $266.43 million in net income (profit) each year or $0.52 on an earnings per share basis. WILLIAM DEMANT/ADR employs 13,280 workers across the globe.
What is WILLIAM DEMANT/ADR's official website?
How can I contact WILLIAM DEMANT/ADR?
WILLIAM DEMANT/ADR's mailing address is Kongebakken 9, Smorum G7, 2765. The company can be reached via phone at 45-3917-7300 or via email at [email protected]
MarketBeat Community Rating for WILLIAM DEMANT/ADR (OTCMKTS WILYY)
MarketBeat's community ratings are surveys of what our community members think about WILLIAM DEMANT/ADR and other stocks. Vote "Outperform" if you believe WILYY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe WILYY will underperform the S&P 500 over the long term. You may vote once every thirty days.
